The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer

Zeppernick, Felix; Meinhold‐Heerlein, Ivo

doi:10.1007/s00404-014-3364-8

Cited by 179 publications

(120 citation statements)

References 8 publications

Supporting

Mentioning

120

Contrasting

Order By: Relevance

“…As the histological types, we adopted the World Health Organization (WHO) classification criteria. The clinical stage was assigned according to the International Federation of Gynecology and Obstetrics (FIGO) staging system (15,16).…”

Section: Methodsmentioning

confidence: 99%

Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator

et al. 2017

View full text Add to dashboard Cite

Abstract. Several previous studies have revealed that the expression of zinc finger E-box binding homeobox 1 (ZEB1) in solid malignancies has an important significance on the clinical outcome of patients. However, the association between ZEB1 expression and survival in patients with epithelial ovarian carcinoma (EOC) remains unclear. The objective of the present study was to examine the extent of ZEB1 expression in EOC using immunohistochemical staining and investigate its association with patient outcome. A total of 40 patients with EOC initially treated with cytoreductive surgery and systematic chemotherapy were enrolled. ZEB1 expression was immunohistochemically categorized as negative, weak, moderate and strong according to the size of the staining area, and intensity. Subsequently, the associations between ZEB1 expression and recurrence/progression-free survival (RFS) rate were examined. The median age of patients in the current study was 54 years old (range, 22-72 years old). Among these patients, 15 (37.5%) exhibited International Federation of Gynecology and Obstetrics stage I disease, and 10 (25.0%), 13 (32.5%), and 2 (5%) had stage II, III, and IV disease, respectively. No patients with negative expression of ZEB1 experienced recurrence. In addition, ZEB1 expression was identified to be a significant predictor of a poorer RFS rate compared with negative expression (negative vs. weak, moderate and strong, P= 0.0126). Furthermore, multivariate analyses revealed that moderate and strong ZEB1 expression levels were significant prognostic indicators of a poorer RFS rate in patients with EOC (hazard ratio, 2.265; 95% confidence interval, 1.072-8.021; P=0.0349). Confining analysis to patients with the clear-cell/mucinous histological type, those with moderate/strong ZEB1 expression demonstrated a significantly poorer RFS rate (P=0.0025). Positive ZEB1 expression may be an indicator to predict unfavorable RFS in patients with EOC.

show abstract

Section: Methodsmentioning

confidence: 99%

Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Lymphatic metastasis is an important malignant progression factor in ovarian carcinoma (40,41). In advanced disease (FIGO stages III-IV) particularly, nodal metastases to the pelvic and para-aortic lymph nodes are common (25). SASH1 expression in ovarian carcinoma tissues from patients with lymph nodes metastases was significantly lower than that in ovarian carcinoma tissues with negative lymph nodes metastases.…”

Section: Discussionmentioning

confidence: 99%

“…All tumor tissue and the adjacent normal ovarian tissue from 79 ovarian carcinoma cases were pathologically verified by the Department of Pathology of the Maternal and Child Health Care Hospital of Nantong. The clinicopathological characteristics of 79 ovarian patients were collected, including age at diagnosis, FIGO stage (25), histological type, and lymph node status. Histological type was classified according to the World Health Organization (WHO) criteria (26).…”

Section: Methodsmentioning

confidence: 99%

Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma

et al. 2016

View full text Add to dashboard Cite

Abstract. SAM-and SH3-domain containing 1 (SASH1) is a recently identified tumor suppressor gene that is required in the tumorigenesis of breast and other solid carcinomas. The SASH1 protein contains SH3 and SAM domains, indicating that it may serve an important role in intracellular signal transduction. The purpose of the present study was to investigate the expression of SASH1 in ovarian carcinoma and the correlation between its expression with clinical pathological features and clinical significance, and the effect of SASH1 on cell proliferation, apoptosis and migration of ovarian SKOV3 cells. The human ovarian carcinoma tissues and adjacent normal tissues were collected following surgery. Reverse transcription-quantitative polymerase chain reaction and western blot analysis were used to detect the expression levels of SASH1 mRNA and protein, respectively. The expression levels of SASH1 mRNA and protein in ovarian carcinoma tissues were significantly lower than that observed in adjacent normal tissues (P<0.05). The expression levels of SASH1 in samples from patients without lymph nodes metastasis and patients with early FIGO stage was lower than those with lymph nodes metastasis and patients with advanced FIGO stage (P<0.05). Flow cytometry analysis and Transwell invasion chamber experiments were used to investigate the effect of SASH1 on the cell proliferation, apoptosis and migration of SKOV3 cells. The recombinant plasmid pcDNA3.1-SASH1 was constructed and transfected into SKOV3 cells. In addition, the SKOV3 cells in the pcDNA3.1-SASH1 group exhibited significantly reduced cell growth, proliferation, and migration ability compared to the empty vector group and normal group (P<0.01). There were a greater number of apoptotic cells in the pcDNA3.1-SASH1 group compared to the empty vector group and normal group (P<0.01). Taken together, these results indicated that SASH1 may be a tumor suppressor gene in ovarian carcinoma, and SASH1 expression inhibited growth, proliferation and migration, and enhanced apoptosis of SKOV3 cells.

show abstract

“…All specimens were used in the present study after obtaining written informed consent from the patients, and ethical approval was provided by the Ethics Review Board of Life Sciences, Zhengzhou University. According to the 2010 International Federation of Gynecology and Obstetrics (FIGO) grading system (14), tumor histological grade was classified as poorly-differentiated (grade 3; 11/80 patients), moderately-differentiated (grade 2; 20/80 patients) or well-differentiated (grade 1; 49/80 patients). Surgical staging was reviewed based on the FIGO staging system as follows: 9 patients were allocated to stage I, 20 patients to stage II, 33 patients to stage III and 18 patients to stage IV.…”

Section: Methodsmentioning

confidence: 99%

Expression and prognostic value of matriptase in ovarian serous adenocarcinoma

Xie

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Previous studies have demonstrated that matriptase is involved in degradation of the extracellular matrix and angiogenesis, and is overexpressed in certain forms of epithelial cancer. The present study aimed to examine matriptase expression in ovarian serous adenocarcinoma, and to investigate its association with clinicopathological characteristics and patient prognosis. Matriptase expression was analyzed in 80 ovarian serous adenocarcinoma and 12 normal ovarian tissue samples by immunohistochemistry. All data were analyzed to evaluate the association between matriptase expression and clinicopathological parameters and overall survival. Immunohistochemistry demonstrated that matriptase protein was significantly overexpressed in the ovarian serous adenocarcinoma tissues compared with the normal ovarian tissues (P=0.0003). Furthermore, matriptase expression was significantly associated with clinical stage (P=0.0077) and lymph node metastasis (P=0.0111). Kaplan-Meier survival curves demonstrated that patients with positive matriptase expression had significantly greater survival times (P=0.0008). Matriptase expression is associated with early stage and a greater survival time; therefore, this protein may function as a novel diagnostic and prognostic marker.

show abstract

The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer

Abstract: The new FIGO classification takes into account the recent findings on the origin, pathogenesis, and prognosis of different ovarian cancer subtypes, summarizes groups of tumors pragmatically, and implies a reproducible and stage-dependent therapeutical approach.

Cited by 179 publications

References 8 publications

Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator

Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator

Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma

Expression and prognostic value of matriptase in ovarian serous adenocarcinoma

Contact Info

Product

Resources

About